As­traZeneca her­alds Tagris­so's OS lead over old TKIs in lung can­cer niche

BARCELONA — As­traZeneca is draw­ing the cur­tains on just how much longer Tagris­so can help non-small cell lung can­cer pa­tients live com­pared to first-gen­er­a­tion ty­ro­sine ki­nase in­hibitors tar­get­ing the EGFR mu­ta­tion, mak­ing a strong case for its front­line use in this niche.

Hav­ing pre­vi­ous­ly scored on the pri­ma­ry end­point of PFS, the phar­ma gi­ant is spelling out the OS da­ta at ES­MO Con­gress 2019: 38.6 months with Tagris­so ver­sus 31.8 months on Tarce­va or Ires­sa, giv­ing rise to a haz­ard ra­tio of 0.799 (p=0.0462).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.